Chunli Medical released its 2026 half-year report. Net profit attributable to the parent in the first half was 120 million yuan, up 4.8% year on year, but operating revenue was 417 million yuan, down 14.5% year on year. Net profit attributable to the parent after deducting non-recurring items was 114 million yuan, up 7.5% year on year. Net operating cash flow was 34.32 million yuan, down 75.7% year on year, and earnings per share were 0.3127 yuan. In the second quarter, operating revenue was 200 million yuan, down 22.4% year on year, and net profit attributable to the parent was 58.25 million yuan, up 3.3% year on year. As of the end of the second quarter, total assets were 3.591 billion yuan, down 1.9% from the end of the previous year, and net assets attributable to the parent were 3.048 billion yuan, up 2.1% from the end of the previous year. The company said its main business is the research, development, production and sales of implantable orthopaedic medical devices. Although operating revenue declined due to the market environment and policy impacts, it achieved steady growth in net profit by optimising its product structure and strengthening its market strategy, and made important progress in 3D printing and biomedical materials.
Beijing Chunlizhengda Medical Instruments Co LtdNet profit up 4.8% despite revenue decline, driven by product mix and market strategy.
